Journal
RHEUMATOLOGY
Volume 58, Issue 1, Pages 5-17Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/key006
Keywords
macrophage activation syndrome; haemophagocytic lymphohistiocytosis; haemophagocytic syndrome; reactive haernophagocytosis; hyperferritinaernia
Categories
Ask authors/readers for more resources
Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome, which if not promptly treated, can lead rapidly to critical illness and death. HLH is termed macrophage activation syndrome (MAS) when associated with rheumatic disease (where it is best characterized in systemic JIA) and secondary HLH (sHLH) when associated with other triggers including malignancy and infection. MAS/sHLH is rare and coupled with its mimicry of other conditions, is underrecognized. These inherent challenges can lead to diagnostic and management challenges in multiple medical specialties including haematology, infectious diseases, critical care and rheumatology. In this review we highlight the pathogenesis of MAS/sHLH including its underlying triggers, key clinical features and diagnostic challenges, prognostic factors and current treatments in adults.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available